PainChek (ASX:PCK) lands US$5B Sabra REIT, 20,000 beds worth A$1.5m

What PainChek Just Secured

PainChek (ASX:PCK) has entered into a Master Services Agreement with Sabra Health Care REIT, a US$5B Nasdaq-listed healthcare property owner. The deal establishes Sabra as a funded distributor of PainChek across its network of 329 facilities in the US and Canada.

The agreement runs for 12 months, with an option to terminate after that period on 90 days’ notice. Sabra will initially fund the deployment of PainChek on behalf of its operating partners, which is important because it reduces the friction for adoption across the network.

The market viewed the announcement favourably, sending the share price up 40% as investors started to factor in the revenue potential that could come from this partnership.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

The Deal Economics, Annual Revenue at Full Deployment

If we look at the pricing economics, PainChek is expected to be paid between A$55 and A$75 per bed under a tiered pricing model. With the initial commitment covering 20,000 beds, that implies potential revenue of around A$1.1M to A$1.5M. The key here is potential based on the deal economics.

What also matters is that as Sabra acquires new facilities or expands existing ones, PainChek can grow alongside that footprint. That creates a revenue base that can build over time through expansion alone.

With Sabra backing the rollout across 329 facilities and telling its operating partners that the funding is already in place as part of the broader operating arrangement, adoption becomes much more straightforward. In practical terms, the decision is far more binary, either on or off, which means there is less room for delays and the PainChek sales cycle should shorten materially.

The North American Aged Care Landscape

North America alone has roughly 2.5 to 3.0 million skilled nursing and senior housing beds across long-term care facilities. Healthcare REITs own about 40% of that base, or around 1 million beds. Sabra alone owns 36,000, making it one of the top five healthcare REITs by property count. Its scale is not exceptional in absolute terms, with larger operators such as Brookdale controlling more than 100,000 beds, but it is still large enough to serve as a meaningful test case for the REIT replicability thesis PainChek is pursuing. If Sabra continues to scale and expand adoption, PainChek becomes a direct beneficiary of that growth.

PainChek’s messaging in this announcement is clearly centred on model replication. Management is positioning Sabra not as a one-off customer, but as a blueprint for how to penetrate the REIT segment at scale. If this approach works, and there are good reasons to think it can, the company may have a repeatable, capital-light playbook it can apply each time it signs a new REIT.

The investor’s takeaway for PCK

What investors will want to watch closely is whether facilities begin cancelling deployments or pushing them back after six months. If that starts happening, it would suggest PainChek’s product is not embedding strongly enough into the workflow to support broader rollout. In that scenario, Sabra would be less likely to expand toward the full 20,000-bed opportunity, which would weaken the market’s confidence in the scalability of the model.

On the other hand, if the rollout tracks to management’s expected timeline, this could become a meaningful high-margin revenue opportunity for the business.

Phase 1 (2026) Initial five operators, with around 3,000 beds deployed by year-end. Revenue of roughly A$195,000 annualised.

Phase 2 (2027) An additional 10 operators in the queue, taking cumulative deployed beds to around 8,000 to 10,000. Revenue ramps to roughly A$650,000 to A$750,000 annualised by year-end.

Phase 3 (2028) Expansion across the remaining portfolio, taking deployment to around 15,000 to 20,000 beds. Revenue reaches roughly A$975,000 to A$1.3 million annualised by year-end.

If PainChek can execute against that pathway, the Sabra agreement moves from being a simple customer win to a scalable, sticky, and attractive recurring revenue stream.